In this work, gadolinium-based carbon nanocapsules are developed as a novel nanotechnology that addresses the shortcomings of current diagnostic and therapeutic methods of stem cell-based cardiomyoplasty. With cardiovascular disease (CVD) responsible for approximately 30% of deaths worldwide, the growing need for improved cardiomyoplasty has spurred efforts in nanomedicine to develop innovative techniques to enhance the therapeutic retention and diagnostic tracking of transplanted cells. Having previously been demonstrated as a high-performance T1-weighted magnetic resonance imaging (MRI) contrast agent, Gadonanotubes (GNTs) are shown for the first time to intracellularly label pig bone marrow-derived mesenchymal stem cells (MSCs). Without the use of a transfection agent, micromolar concentrations of GNTs deliver up to 10^9 Gd(III) ions per cell, allowing for MSCs to be visualized in a 1.5 T clinical MRI scanner. The cellular response to the intracellular incorporation of GNTs is also assessed, revealing that GNTs do not compromise the viability, differentiation potential, or phenotype characteristics of the MSCs. However, it is also found that GNT-labeled MSCs exhibit a decreased response to select cell adhesion proteins and experience a non-apoptotic, non-proliferative cell cycle arrest, from which the cells recover 48 h after GNT internalization. In tandem with developing GNTs as a new stem cell diagnostic agent, this current work also explores for the first time the therapeutic application of the magnetically-active GNTs as a magnetic facilitator to increase the retention of transplanted stem cells during cardiomyoplasty. In vitro flow chamber assays, ex vivo perfusion experiments, and in vivo porcine injection procedures all demonstrate the increased magnetic-assisted retention of GNT-labeled MSCs in the presence of an external magnetic field. These studies prove that GNTs are a powerful ‘theranostic’ agent that provides a novel platform to simultaneously monitor and improve the therapeutic nature of stem cells for the treatment of CVD. It is expected that this new nanotechnology will further catalyze the development of cellular cardiomyoplasty and other stem cell-based therapies for the prevention, detection, and treatment of human diseases.

The heart does not regenerate new functional tissue when myocardium dies following coronary artery occlusion, or is defective. Ventricular restoration involves excising the infarct and replacing it with a cardiac patch to restore the heart to a more efficient condition. The goal of this study was to design and develop a myocardial patch to replace myocardial infarctions. A basic design was developed that is composed of 3D microfibrous mats that house mesenchymal stem cells (MSCs) from umbilical cord matrix (Wharton&rsquo / s Jelly) aligned parallel to each other, and biodegradable macroporous tubings to supply growth media into the structure. Poly(glycerol sebacate) (PGS) prepolimer was synthesized and blended with P(L-D,L)LA and/or PHBV, to produce aligned microfiber (dia 1.16 - 1.37 &amp / #956 / m) mats and macroporous tubings. Hydrophilicity and softness of the polymer blends were found to be improved as a result of PGS introduction. The Wharton&rsquo / s Jelly (WJ) MSCs were characterized by determination of their cell surface antigens with flow cytometry and by differentiating them into cells of mesodermal lineage (osteoblasts, adipocytes, chondrocytes). Cardiomyogenic differentiation potential of WJ MSCs in presence of differentiation factors was studied with RT-PCR and immunocytochemistry. WJ MSCs expressed cardiomyogenic transcription factors even in their undifferentiated state. Expression of a ventricular sarcomeric protein was observed upon differentiation. The electrospun, aligned microfibrous mats of PHBV-P(L-D,L)LA-PGS blends allowed penetration of WJ MSCs and improved cell proliferation. To obtain the 3D myocardial graft, the WJ MSCs were seeded on the mats, which were then wrapped around macroporous tubings. The 3D construct (4 mm x 3.5 cm x 2 mm) was incubated in a bioreactor and maintained the uniform distribution of aligned cells for 2 weeks. The positive effect of nutrient flow within the 3D structure was significant. This study represents an important step towards obtaining a thick, autologous myocardial patch, with structure similar to native tissue and capability to grow, for ventricular restoration.

Non-healing bone defects have a significant socioeconomic impact in the U.S. with approximately 600,000 bone grafting procedures performed annually. Autografts and allografts are clinically the most common treatments; however, autologous donor bone is in limited supply, and allografts often have poor mechanical properties. Therefore, tissue engineering and regenerative medicine strategies are being developed to address issues with clinical bone grafting. The overall objective of this work was to develop bone tissue engineering strategies that enhance healing of orthotopic defects by targeting specific osteogenic cell signaling pathways. The general approach included the investigation of two different tissue engineering strategies, which both focused on directed osteoblastic differentiation to promote bone formation. In the first cell-based strategy, we hypothesized that constitutive overexpression of the osteoblast-specific transcription factor, Runx2, in bone marrow stromal cells (BMSCs) would promote orthotopic bone formation in vivo. We tested this hypothesis by delivering Runx2-modified BMSCs on synthetic scaffolds to critically-sized defects in rats. We found that Runx2-modified BMSCs significantly increased orthotopic bone formation compared to empty defects, cell-free scaffolds and unmodified BMSCs. This gene therapy approach to bone regeneration provides a mineralizing cell source which has clinical relevance. In the second biomaterial-based strategy, we hypothesized that incorporation of the collagen-mimetic peptide, GFOGER, into synthetic bone scaffolds would promote orthotopic bone formation in vivo without the use of cells or growth factors. We tested this hypothesis by passively adsorbing GFOGER onto poly-caprolactone (PCL) scaffolds and implanting them into critically-sized orthotopic defects in rats. We found that GFOGER-coated scaffolds significantly increased bone formation compared to uncoated scaffolds in a dose dependent manner. Development of this cell-free strategy for bone tissue engineering provides an inexpensive therapeutic alternative to clinical bone defect healing, which could be implemented as a point of care application. Both strategies developed in this work take advantage of specific osteoblastic signaling pathways involved in bone healing. Further development of these tissue engineering strategies for bone regeneration will provide clinically-relevant treatment options for healing large bone defects in humans by employing well-controlled signals to promote bone formation and eliminating the need for donor bone.

Ligament/tendon tissue engineering has the potential to provide therapies that overcome the limitations of incomplete natural healing responses and inadequate graft materials. While ligament/tendon fibroblasts are an obvious choice of cell type for these applications, difficulties associated with finding a suitable cell source have limited their utility. Mesenchymal stem cells/marrow stromal cells (MSCs) are seen as a viable alternative since they can be harvested through routine medical procedures and can be differentiated toward a ligament/tendon fibroblast lineage. Further study is needed to create an optimal biomaterial/biomechanical environment for ligament/tendon fibroblastic differentiation of MSCs. The overall goal of this dissertation was to improve the understanding of the role that biomechanical stimulation and the biomaterial environment play, both independently and combined, on human MSC (hMSC) differentiation toward a ligament/tendon fibroblast phenotype. Specifically, the effects of cyclic tensile stimuli were studied in a biomaterial environment that provided controlled presentation of biological moieties. The influence of an enzymatically-degradable biomaterial environment on hMSC differentiation was investigated by creating biomaterials containing enzymatically-cleavable moieties. The role that preculture may play in tensile responses of hMSCs was also explored. Together, these studies provided insights into the contributions of the biomaterial and biomechanical environment to hMSC differentiation toward a ligament/tendon fibroblast phenotype.

Mesenchymal stem cells (MSCs) are bone marrow derived multipotent cells with the ability to self-renew and differentiate into multiple connective cell lineages. In vivo, MSCs travel from the bone-marrow to the inflammatory sites and actively participate in remodeling and regeneration process under the influence of soluble growth factors. Due to these inherent properties, MSCs have emerged as an ideal candidate for diverse regenerative therapeutic applications. The development of MSC-based therapies requires in vitro expansion of MSCs; however, MSC expansion results in phenotypical changes that have limited its efficacy upon reintroduction in vivo. In order to increase the efficacy of MSC-based therapeutics, it is critical for us to improve the current understanding of MSC interactions with its niche specific factors and explore new methods to enhance MSC function in vivo. We used tumor conditioned media, which contains soluble factors secreted by tumor cells in culture (TCM), and inflammatory niche-specific soluble factors, such as platelet derived growth factor (PDGF) and transforming growth factor-β1 (TGF-β1), to characterize the mechanical response of MSCs. The intracellular mechanical properties of MSCs were dramatically altered in response to soluble factors and MSCs displayed cytosolic stiffening in response to TCM and TGF-β1. Although PDGF treated cells did not elicit any mechanical response, blocking PDGF signaling with a small molecule inhibitor reversed the stiffening response in TGF-β1 treated cells, indicating crosstalk between these two pathways is essential in TGF-β1 mediated cell stiffening. Furthermore, a genome-wide microarray analysis revealed TGF-β1 dependent regulation of cytoskeletal actin-binding protein (ABP) genes. Actin crosslinking and bundling protein genes, which regulate cytosolic rheology through changes in semiflexible actin polymer meshworks, were upregulated with TGF-β1 treatment. Since TGF-β1 treatment profoundly altered the MSC phenotype after relatively short exposure times, we sought to understand if pretreated cells could sustain these enhanced characteristics leading to higher efficacy in vivo. We found that MSCs pretreated with TGF-β1 displayed enhanced adhesive properties while maintaining the expression profile of surface adhesion molecules even after removal of stimulus. Additionally, pretreated MSCs exposed to lineage specific induction media, demonstrated superior differentiation potential along multiple lineages. Based on the large number of sustained changes, TGF-β1 pretreated cells were used to treat full thickness skin wounds for in vivo wound healing model to determine their therapeutic efficacy. TGF-β1 pretreated MSCs increased wound closure rate and displayed enhanced migration of MSCs towards the center of the wound compared to the control cells. In conclusion, soluble factor pretreated MSCs with altered mechanical properties displayed significantly improved cell functions leading to highly efficient tissue regeneration in vivo. Mechanical priming of MSCs with niche specific factors prior to transplantation can become a viable strategy to maximize their therapeutic potential.

No description available.

The aim of biomaterials design is to create an artificial environment that mimics the in vivo extracellular matrix for optimized cell interactions. A precise synergy between the scaffolding material, bioactivity, and cell type must be maintained in an effective biomaterial. In this work, we present a technique of nanofabrication that creates chemically nanopatterned bioactive silicon surfaces for cell studies. Using nanoimprint lithography, RGD and mimetic BMP-2 peptides were covalently grafted onto silicon as nanodots of various dimensions, resulting in a nanodistribution of bioactivity. To study the effects of spatially distributed bioactivity on cell behavior, mesenchymal stem cells (MSCs) were cultured on these chemically modified surfaces, and their adhesion and differentiation were studied. MSCs are used in regenerative medicine due to their multipotent properties, and well-controlled biomaterial surface chemistries can be used to influence their fate. We observe that peptide nanodots induce differences in MSC behavior in terms of cytoskeletal organization, actin stress fiber arrangement, focal adhesion (FA) maturation, and MSC commitment in comparison with homogeneous control surfaces. In particular, FA area, distribution, and conformation were highly affected by the presence of peptide nanopatterns. Additionally, RGD and mimetic BMP-2 peptides influenced cellular behavior through different mechanisms that resulted in changes in cell spreading and FA maturation. These findings have remarkable implications that contribute to the understanding of cell-extracellular matrix interactions for clinical biomaterials applications.

Mesenchymal stromal cells (MSC) are bone marrow-derived, non-hematopoietic progenitors that are amenable to genetic engineering, making them attractive delivery vehicles for therapeutic proteins. However, limited transplanted cell survival compromises the efficacy of MSC-based gene therapy. We hypothesized that co-implantation of insulin-like growth factor-1 (IGF-I)-overexpressing MSC (MSC-IGF) would improve MSC-based therapy of anemia by providing paracrine support to erythropoietin (EPO)-secreting MSC (MSC-EPO). Murine MSC were found to express the IGF-I receptor and be responsive to IGF-I stimulation. IGF-I also improved MSC survival in vitro. MSC were admixed in a bovine collagen matrix and implanted by subcutaneous injection in a murine model of chronic renal failure. Mice receiving MSC-EPO co-implanted with MSC-IGF experienced a greater and significantly sustained elevation in hematocrit compared to controls; heart function was also improved. Co-implantation of MSC-IGF therefore represents a promising new strategy for enhancing implanted cell survival, and improving cell-based gene therapy of renal anemia.

Ziel der vorliegenden Arbeit war die biologische Charakterisierung neuartiger nanostrukturierter und für die Knochenregeneration geeigneter Calciumphosphatzemente (CPC). Hierzu wurde ein aus α-Tricalciumphosphat, Calciumhydrogenphosphat, gefälltem Hydroxylapatit und Calciumcarbonat bestehender CPC verwendet, der mit den Biomolekülen Cocarboxylase, Glucuronsäure, Weinsäure, Glucose-1-phosphat, Arginin, Lysin und Asparaginsäure-Natriumsalz modifiziert wurde. Ermittelt wurde dabei der Einfluss der Modifikationen auf die Proteinadsorption und die Biokompatibilität. In Vorversuchen wurden die Zementmodifikationen hinsichtlich ihrer Bindungskapazität für humane Serumproteine und für das knochenspezifische Protein Osteocalcin (OC) sowie hinsichtlich ihrer Eignung für die Adhäsion, Proliferation und osteogene Differenzierung von humanen fötalen Osteoblasten (hFOB 1.19) und humanen mesenchymalen Stammzellen (hMSC) untersucht. Dabei erwiesen sich die Modifikationen mit Cocarboxylase, Arginin und Asparaginsäure-Natriumsalz als besonders günstig. Mit diesen „Favoriten“ erfolgte eine detailliertere Analyse der Adsorption humaner und boviner Serumproteine sowie der knochen-spezifischen Proteine Osteocalcin, BMP-2 und VEGF. Dabei führte sowohl der Zusatz von Cocarboxylase, als auch der von Arginin und Asparaginsäure-Natriumsalz zu einer erhöhten Adsorption von Serumproteinen. Die Bindungsaffinität des Basiszements gegenüber Osteocalcin, BMP-2 und VEGF konnte durch Funktionalisierung mit Arginin gesteigert werden. Während die Modifizierung mit Cocarboxylase nur die VEGF-Adsorption förderte, bewirkte der Zusatz von Asparaginsäure-Natriumsalz eine Erhöhung der Osteocalcin- und BMP-2-Adsorption. Bedingt durch die größere spezifische Oberfläche der noch nicht abgebundenen Zemente, war die Menge adsorbierter Proteine auf frisch hergestellten Zementproben im Vergleich zu abgebundenen und ausgehärteten Zementen signifikant höher. Die Eignung der ausgewählten Zementvarianten als Knochenersatzmaterialien wurde mithilfe humaner mesenchymaler Stammzellen zweier verschiedener Spender getestet. Bei Verwendung abgebundener und ausgehärteter Zemente waren die hMSC in der Lage, auf allen Modifikationen zu adhärieren, zu proliferieren und in die osteogene Richtung zu differenzieren. Eine vorherige Inkubation der Zementproben mit humanem Serum förderte dabei vor allem die Zelladhäsion. Weiterhin konnte gezeigt werden, dass hMSC im Gegensatz zu anderen Studien auch auf frisch hergestellten Zementproben adhärieren, proliferieren und differenzieren können. Die Modifizierung des Basiszements mit Cocarboxylase führte hierbei zu einer gegenüber den anderen Modifikationen signifikant erhöhten Zelladhäsion und -vitalität. Neben den verschieden modifizierten Pulver/Flüssigkeitszementen wurden im Rahmen dieser Arbeit neuartige ready-to-use Zementpasten untersucht. Diese zeigten allerdings im Vergleich zu den herkömmlichen Zementen eine geringere Proteinbindungsaffinität. HMSC, die auf den Pastenzementen kultiviert wurden, war es wiederum möglich zu adhärieren, zu proliferieren und den osteoblastenspezifischen Marker Alkalische Phosphatase zu exprimieren. Hinsichtlich ihrer Biokompatibilität sind sie damit vergleichbar zu den herkömmlichen Pulver/Flüssigkeitszementen.

A engenharia de tecido ósseo associando células-tronco mesenquimais (CTMs) a biomateriais tem sido proposta como tratamento potencial para o reparo de defeitos ósseos, constituindo uma abordagem nova na área da medicina regenerativa e de amplo interesse para as áreas de cirurgia buco-maxilo-facial e ortopedia. A seleção das CTMs mais adequadas e o método utilizado para carreá-las nos sítios de defeitos ósseos são fatores importantes para o sucesso do tratamento. Como a osteoporose reduz a capacidade de regeneração dos ossos, seria de grande importância que a engenharia do tecido ósseo pudesse ser aplicada com sucesso nessa patologia. Assim, foi avaliado o potencial das CTMs de medula óssea (CTMs-MO) e de tecido adiposo (CTMs-TA) associadas ao arcabouço de vitrocerâmica BioS-2P ou a membrana de P(VDF-TrFE)/BT no reparo de defeitos ósseos em ratas osteoporóticas. A osteoporose foi induzida por ovariectomia e comprovada pela análise microtomográfica dos fêmures. Nas ratas osteoporóticas foram criados defeitos ósseos nas calvárias que foram tratados com implantação de BioS-2P associado à CTMs-MO e CTMs-TA ou com a implantação de membrana de P(VDF-TrFE)/BT combinada com a injeção de CTMs-MO e CTMs-TA. Ao final de 4 semanas, as análises microtomográficas e histológica mostraram que não houve formação óssea nos defeitos sem qualquer tratamento, mas nos defeitos tratados com implantação de BioS-2P ou membrana de P(VDF-TrFE)/BT houve formação óssea independente da presença de CTMs. Apenas os defeitos tratados com membrana de P(VDF-TrFE)/BT e injeção de CTMs-MO apresentaram maior formação óssea, mas não ocorreu a regeneração. / Bone tissue engineering based on the combination of mesenchymal stem cells (MSCs) and biomaterials, has been proposed as a potential treatment for the repair of bone defects, constituting a new approach in the field of regenerative medicine and of interest to the areas of oral and maxillofacial surgery and orthopedics. To select the most suitable MSCs and an efficient method to carry them to the bone defects are the key for the successful treatment. Considering that osteoporosis represents a challenge situation, it would be of the utmost importance that bone tissue engineering could be used in this pathological condition. Thus, the aim of this study was to evaluate the potential of MSCs harvested from bone marrow (MSCs-BM) and from adipose tissue (MSCs-AT) associated to a vitreous scaffold (BioS-2P) or to a membrane of P(VDF-TrFE)/BT in regenerate bone defects created in osteoporotic rats. Osteoporosis was induced by ovariectomy and confirmed by microtomography of the femurs. Defects created in calvaria of osteoporotic rats were implanted with either Bios-2P seeded with MSCs-BM and MSCs-AT or a membrane of P(VDF-TrFE)/BT combined with injection of MSCs-BM and MSCs-AT. After 4 weeks, microtomography and histological analyses showed that there was no bone formation in untreated defects but in those treated with BioS-2P or membrane of P(VDF-TrFE)/BT there was bone formation irrespective of the presence of MSCs. Only defects treated with membrane of P(VDF-TrFE)/BT and MSCs-BM injection resulted in greater bone formation but there was not full bone regeneration.